Cancer Treatments

Lazertinib (Lazcluze™), in combination with amivantamab, is the first and currently the only first-line chemotherapy-free combination treatment for adults with certain types of locally advanced or metastatic non-small cell lung cancer. 

On November 15, 2024, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj^®), a menin inhibitor, for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients aged one year and older.

On October 29, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to asciminib (Scemblix^®) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

On October 18, 2024, the U.S. Food and Drug Administration (FDA) approved zolbetuximab-clzb (Vyloy^™), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.

On October 10, 2024, the U.S. Food and Drug Administration (FDA) approved inavolisib (Itovebi^™) with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-variant, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa^®) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplantation.

On September 19, 2024, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (Rybrevant^®) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution variants whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

On September 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda^®) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).

On September 17, 2024, the U.S. Food and Drug Administration (FDA) approved ribociclib (Kisqali^®) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative stage II and III early breast cancer with a high risk for recurrence. Additionally, FDA approved the ribociclib and letrozole co-pack (Kisqali^® Femara^® Co-Pack) for the same indication.

On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection for all the adult indications for the IV formulation of atezolizumab (Tecentriq^®), including non-small cell lung cancer (NSCLC), small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.